Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VTVT Low Float Bio Tech Bottom of the Chart VTVT Reminds me of AQXP Company has other drugs in its pipeline Should have Positive Phase 2 Results Coming out soon its Diabities drug. AQXP Had a simliar setup one of the drugs it was working on had bad news stock tanked on the news then a few days later the company had positive news on its other drug Phase 2 results and the stock Soared the shorts got KILLED The stock went from 2$ to 55$ in Days... VTVT Low Float Bio Tech Bottom of the Chart W other drugs in the pipeline
http://www.vtvtherapeutics.com/pipeline
Should have Positive Phase 2 Results Coming out soon on its Diabities Drug The Market Potential with this drug is huge given that Diabities market share continues to grow and is currently valued at 66 Billion Dollars
https://www.statista.com/statistics/373981/global-spending-on-diabetes-by-market/
Clinical Data
TTP399 has been studied in a series of phase 1 and phase 2 clinical trials. In all studies, TTP399 has been safe and well tolerated, with no increased incidence of hypoglycemia compared to placebo. The results of these trials, suggest that our approach to glucokinase activation will avoid safety and tolerability issues associated with other GKAs, such as activation of glucokinase in the pancreas, stimulation of insulin secretion independent of glucose, hypoglycemia, increased lipids and liver toxicity. Further, we believe that TTP399 will compare favorably with other products in the market, as our trials have indicated that TTP399 may have higher efficacy than competing products, the ability to normalize HbA1c, and no contraindication for renal impairment.
We have completed a Phase 2 clinical trial of TTP399, a randomized, double-blind, parallel-group, placebo-controlled, six-week, multiple dose study in 151 type 2 diabetic patients whose glycemic parameters were not well-controlled on metformin. The trial was designed to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in formulation 1 and was conducted at 11 centers in the United States. Patients were randomized into four arms: TTP399 400 mg BID, TTP399 800 mg QD, TTP399 800 mg BID, and placebo. All patients remained on consistent doses of metformin throughout the trial.
VTVT Low Float Bio Tech Bottom of the Chart VTVT Reminds me of AQXP Company has other drugs in its pipeline Should have Positive Phase 2 Results Coming out soon its Diabities drug. AQXP Had a simliar setup one of the drugs it was working on had bad news stock tanked on the news then a few days later the company had positive news on its other drug Phase 2 results and the stock Soared the shorts got KILLED The stock went from 2$ to 55$ in Days... VTVT Low Float Bio Tech Bottom of the Chart W other drugs in the pipeline
http://www.vtvtherapeutics.com/pipeline
Should have Positive Phase 2 Results Coming out soon on its Diabities Drug The Market Potential with this drug is huge given that Diabities market share continues to grow and is currently valued at 66 Billion Dollars
https://www.statista.com/statistics/373981/global-spending-on-diabetes-by-market/
Clinical Data
TTP399 has been studied in a series of phase 1 and phase 2 clinical trials. In all studies, TTP399 has been safe and well tolerated, with no increased incidence of hypoglycemia compared to placebo. The results of these trials, suggest that our approach to glucokinase activation will avoid safety and tolerability issues associated with other GKAs, such as activation of glucokinase in the pancreas, stimulation of insulin secretion independent of glucose, hypoglycemia, increased lipids and liver toxicity. Further, we believe that TTP399 will compare favorably with other products in the market, as our trials have indicated that TTP399 may have higher efficacy than competing products, the ability to normalize HbA1c, and no contraindication for renal impairment.
We have completed a Phase 2 clinical trial of TTP399, a randomized, double-blind, parallel-group, placebo-controlled, six-week, multiple dose study in 151 type 2 diabetic patients whose glycemic parameters were not well-controlled on metformin. The trial was designed to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in formulation 1 and was conducted at 11 centers in the United States. Patients were randomized into four arms: TTP399 400 mg BID, TTP399 800 mg QD, TTP399 800 mg BID, and placebo. All patients remained on consistent doses of metformin throughout the trial.
VTVT Reminds me of AQXP Company has other drugs in its pipeline Should have Positive Phase 2 Results Coming out soon its Diabities drug. AQXP Had a simliar setup one of the drugs it was working on had bad news stock tanked on the news then a few days later the company had positive news on its other drug Phase 2 results and the stock Soared the shorts got KILLED The stock went from 2$ to 55$ in Days... VTVT Low Float Bio Tech Bottom of the Chart W other drugs in the pipeline
http://www.vtvtherapeutics.com/pipeline
Should have Positive Phase 2 Results Coming out soon on its Diabities Drug The Market Potential with this drug is huge given that Diabities market share continues to grow and is currently valued at 66 Billion Dollars
https://www.statista.com/statistics/373981/global-spending-on-diabetes-by-market/
Clinical Data
TTP399 has been studied in a series of phase 1 and phase 2 clinical trials. In all studies, TTP399 has been safe and well tolerated, with no increased incidence of hypoglycemia compared to placebo. The results of these trials, suggest that our approach to glucokinase activation will avoid safety and tolerability issues associated with other GKAs, such as activation of glucokinase in the pancreas, stimulation of insulin secretion independent of glucose, hypoglycemia, increased lipids and liver toxicity. Further, we believe that TTP399 will compare favorably with other products in the market, as our trials have indicated that TTP399 may have higher efficacy than competing products, the ability to normalize HbA1c, and no contraindication for renal impairment.
We have completed a Phase 2 clinical trial of TTP399, a randomized, double-blind, parallel-group, placebo-controlled, six-week, multiple dose study in 151 type 2 diabetic patients whose glycemic parameters were not well-controlled on metformin. The trial was designed to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in formulation 1 and was conducted at 11 centers in the United States. Patients were randomized into four arms: TTP399 400 mg BID, TTP399 800 mg QD, TTP399 800 mg BID, and placebo. All patients remained on consistent doses of metformin throughout the trial.
VTVT Reminds me of AQXP Company has other drugs in its pipeline Should have Positive Phase 2 Results Coming out soon its Diabities drug. AQXP Had a simliar setup one of the drugs it was working on had bad news stock tanked on the news then a few days later the company had positive news on its other drug Phase 2 results and the stock Soared the shorts got KILLED The stock went from 2$ to 55$ in Days... VTVT Low Float Bio Tech Bottom of the Chart W other drugs in the pipeline
http://www.vtvtherapeutics.com/pipeline
Should have Positive Phase 2 Results Coming out soon on its Diabities Drug The Market Potential with this drug is huge given that Diabities market share continues to grow and is currently valued at 66 Billion Dollars
https://www.statista.com/statistics/373981/global-spending-on-diabetes-by-market/
Clinical Data
TTP399 has been studied in a series of phase 1 and phase 2 clinical trials. In all studies, TTP399 has been safe and well tolerated, with no increased incidence of hypoglycemia compared to placebo. The results of these trials, suggest that our approach to glucokinase activation will avoid safety and tolerability issues associated with other GKAs, such as activation of glucokinase in the pancreas, stimulation of insulin secretion independent of glucose, hypoglycemia, increased lipids and liver toxicity. Further, we believe that TTP399 will compare favorably with other products in the market, as our trials have indicated that TTP399 may have higher efficacy than competing products, the ability to normalize HbA1c, and no contraindication for renal impairment.
We have completed a Phase 2 clinical trial of TTP399, a randomized, double-blind, parallel-group, placebo-controlled, six-week, multiple dose study in 151 type 2 diabetic patients whose glycemic parameters were not well-controlled on metformin. The trial was designed to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in formulation 1 and was conducted at 11 centers in the United States. Patients were randomized into four arms: TTP399 400 mg BID, TTP399 800 mg QD, TTP399 800 mg BID, and placebo. All patients remained on consistent doses of metformin throughout the trial.
VHC Awarded 503 Million Dollars Apple ordered to pay Jury awarded apple more news to follow damages and penatlys could push this award in excess of 1 Billion Dollars
CNAT Only DRUG FAILED OUCH UGLY Book value only 93 cents but Company is burning 33 Million dollars a year This could get UGLY another EDGE Strong Sell that one drug failed stock traded 3$ in AH then Crashed to under a 1$ within days UGLY BagHolders and anyone that bought in got CRUSHED
http://schrts.co/zK6uBH
OREX May need to bring Oprah on board to help market there new FDA Approved Diet and Weight Loss pill would go perfect match W Weight Watchers
CHEK New #1 Stock Pick Revolutionary New way to Screen for Colon Cancer Under 1$ W Huge Upside Similar Company got bought out for 860 Million Dollars https://seekingalpha.com/instablog/902464-hawkinvest/5103179-check-cap-potential-revolutionize-diagnostics-1-stock-offers-major-upside
$CHEK New #1 Stock Pick Revolutionary New way to Screen for Colon Cancer Under 1$ W Huge Upside Similar Company got bought out for 860 Million Dollars https://seekingalpha.com/instablog/902464-hawkinvest/5103179-check-cap-potential-revolutionize-diagnostics-1-stock-offers-major-upside
CHEK News W GE Coming
http://ir.check-cap.com/2017-12-05-Check-Cap-Announces-Advancement-in-GE-Healthcare-Manufacturing-Collaboration
This was from 2 months ago they just got European approval should have news coming soon with GE
They should have News W GE Coming Soon
They are also seeking FDA Approval & They have GE Partnership this could become the new normal way to screen for cancer in the US and Europe Company should try to work a partnership with the American Cancer Society and the CDC in the US to push for cancer screening as lives can be saved if this is caught early and with Chek Cap simple as taking a pill to get screened
ICLK New IPO Just opened really like this one company works with some of the biggest companies in the world including Google Apple Facebook Goldman Sachs and many many more!
www.i-click.com scroll down to the bottom of the page under partners''
Same underwritters as LFIN Low Float
ICLK New IPO Just opened really like this one company works with some of the biggest companies in the world including Google Apple Facebook Goldman Sachs and many many more!
www.i-click.com scroll down to the bottom of the page under partners
ICLK New IPO Just opened really like this one company works with some of the biggest companies in the world including Google Apple Facebook Goldman Sachs and many many more!
www.i-click.com scroll down to the bottom of the page under partners
This setup reminds me of KBIO PZRX Company needs to focus its Resources on #BitCoin & #CryptoCurrencys Huge Potential here sometimes a company has to adapt to change with the market... Take RIOT For example was a BioTech company changed to the hot BitCoin Cryptocurrency and the stock and its shareholders have been rewarded stock has gone from 4$ to 40$+ of LFIN 5$ to 140$ in Days PZRX Reminds me of KBIO That stock filed bankruptcy then ran like a bat out of hell from 40 cents to 40$ in days
New 5 Million Dollar Contract announced last week Link
https://finance.yahoo.com/news/radisys-secures-5-million-order-210500710.html
25 Million Volume This Week VS 30 Million Share Float
Company traded nearly 25 Million shares this week VS a 30 Million share float and that was with the largest shareholder adding to there position so the true float is much much smaller look for some new 13D Filers to come out next week
Company has 4 Major Deals Coming per Latest CC
https://seekingalpha.com/a/2gcm6?p=djnw
BAA Yahoo Price Target is 155$ Per Share
BAA Going Green Wow!!! First Green on this stock in FOREVER
Billion Drug That what can happen....
New Institution Buying SABBY MANAGEMENT, LLC 09/30/2017 707,300 707,300 New 1,202
ASCEND CAPITAL, LLC 09/30/2017 526,430 526,430 New 895
GHOST TREE CAPITAL, LLC 09/30/2017 275,000 275,000 New 468
CASTLE HOOK PARTNERS LP 09/30/2017 266,850 266,850 New 454
LAURION CAPITAL MANAGEMENT LP 09/30/2017 206,475 206,475 New 351
BRIDGEWAY CAPITAL MANAGEMENT INC 09/30/2017 193,900 193,900 New 330
ISZO CAPITAL MANAGEMENT LP 03/31/2017 186,399 186,399 New 317
HAP TRADING, LLC 09/30/2017 172,384 172,384 New 293
BALYASNY ASSET MANAGEMENT LLC 09/30/2017 165,739 165,739 New 282
HIGHBRIDGE CAPITAL MANAGEMENT LLC 09/30/2017 150,302 150,302 New 256
JANE STREET GROUP, LLC 09/30/2017 130,000 130,000 New 221
JEFFERIES GROUP LLC 09/30/2017 108,931 108,931 New 185
POINT72 ASSET MANAGEMENT, L.P. 09/30/2017 100,000 100,000 New 170
TWO SIGMA ADVISERS, LP 09/30/2017 95,000 95,000 New 162
FT OPTIONS LLC 09/30/2017 91,440 91,440 New 155
http://www.nasdaq.com/symbol/vsar/institutional-holdings/new
Lots of New institutions Buying
BAA 2$ Book value per share according to yahoo finance
VSAR The Drug clearly works Sounds like they should have ran the trial in various dosages to get a better feel for what dosage works best also the company should have tried different intervals like once a week and every 2 weeks trials to once again get more data and compare actually with the results that they turned in there results would probably be BETTER Then the current drug on the market that is taken daily i think that if the company gave a higher dosage there drug would work better then the current drug on the market.
Sounds like to me they shouldn't give up on this drug tho they simply need to adjust a few variables the dosing and timing that is even try every week as opposed to daily with a higher dosage and i bet money that this companies drug would have better results then the current drug on the market and not only that would only have to be taken once a week compared to everyday for the current drug...
The company also has Phase 2 Results due anytime
Some links
https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10089620/versartis-somavaratan-still-has-a-path-forward-cantor-r
https://www.fiercebiotech.com/biotech/phase-3-flop-puts-versartis-life-support
https://www.biospace.com/article/releases/versartis-twice-monthly-somavaratan-for-pediatric-growth-hormone-deficiency-to-be-featured-in-oral-and-poster-presentations-at-b-impe-2017-b-/
So clearly the drug does work like i said the company failed in my view by doing a limited study of only a single dosage and once every 2 weeks
They should have done different dosage levels and also at different intervals like a higher dosage every week
Basically they should have tried a few different options I belive that by increasing the dosage and giving it every week as opposed to every 2 weeks the results would be BETTER Then what is currently avaible on the market that has to be taken daily.
VSAR The Drug clearly works Sounds like they should have ran the trial in various dosages to get a better feel for what dosage works best also the company should have tried different intervals like once a week and every 2 weeks trials to once again get more data and compare actually with the results that they turned in there results would probably be BETTER Then the current drug on the market that is taken daily i think that if the company gave a higher dosage there drug would work better then the current drug on the market.
Sounds like to me they shouldn't give up on this drug tho they simply need to adjust a few variables the dosing and timing that is even try every week as opposed to daily with a higher dosage and i bet money that this companies drug would have better results then the current drug on the market and not only that would only have to be taken once a week compared to everyday for the current drug...
The company also has Phase 2 Results due anytime
Some links
https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10089620/versartis-somavaratan-still-has-a-path-forward-cantor-r
https://www.fiercebiotech.com/biotech/phase-3-flop-puts-versartis-life-support
https://www.biospace.com/article/releases/versartis-twice-monthly-somavaratan-for-pediatric-growth-hormone-deficiency-to-be-featured-in-oral-and-poster-presentations-at-b-impe-2017-b-/
So clearly the drug does work like i said the company failed in my view by doing a limited study of only a single dosage and once every 2 weeks
They should have done different dosage levels and also at different intervals like a higher dosage every week
Basically they should have tried a few different options I belive that by increasing the dosage and giving it every week as opposed to every 2 weeks the results would be BETTER Then what is currently avaible on the market that has to be taken daily.
The 12-month HV for PP patients receiving somavaratan twice monthly was 9.71 cm, versus 10.63 cm for those receiving Genotropin daily.
Looks like they did there study wrong i mean the other drug was given DAILY and there drug was only given twice a month i mean come on i am sure that the other drug is going to work better since it was given EVERYDAY VS There drug that was only given twice a month
they need to try this study again and give there drug daily like the other drug is given and then compare those results
Baker Brothers Buying
VSAR Going to Pull a OTIC??
FTFT Chart
http://stockcharts.com/h-sc/ui?s=FTFT&p=W&b=5&g=0&id=p39126546967
Not sure about this one Low Float Toughts??
FTFT Chart Low Float
http://stockcharts.com/h-sc/ui?s=FTFT&p=W&b=5&g=0&id=p39126546967
Not sure about this one Low Float Toughts??
FTFT Chart
http://stockcharts.com/h-sc/ui?s=FTFT&p=W&b=5&g=0&id=p39126546967
Not sure about this one Low Float Toughts??
132.3 Stockholders' equity VS 9 Million market cap attributable to Future FinTech was $132.3 million as of June 30, 2017
FTFT Book Value=25$ Per Share
FTFT 13D Filings Looks like nearly ALL The shares are owned Actually OVER 100%
https://fintel.io/doc/www.sec.gov/Archives/edgar/data/1558443/000121390017010379/sc13d1017a5skypeople_future.htm
I went through and added up all the shares and it comes out to 122% of all the shares are owned by these 13D Filers you say how can they own over 100% of the shares well if you take into account the 25% short interest there ya go
This was over 20$+ not that long ago virtually NO FLOAT
Also Confintantal agreement filing as well
Book value is at 25$ per share
https://finance.yahoo.com/quote/FTFT/key-statistics?p=FTFT
Given the fact that there is virtually NO Float to trade on this one thing all ready trading next to no volume because well there is virtually no shares left for the public to trade and the chart this was 20$+ not that long ago any news and this thing can fly and burn the shorts all the way up
Company is also spose to close on a 100 Million Dollar deal by the end of the year so that news could come at anytime... Bottom of the chart dirt cheap down here 97 Million in retained earnings
FTFT 13D Filings Looks like nearly ALL The shares are owned Actually OVER 100%
https://fintel.io/doc/www.sec.gov/Archives/edgar/data/1558443/000121390017010379/sc13d1017a5skypeople_future.htm
I went through and added up all the shares and it comes out to 122% of all the shares are owned by these 13D Filers you say how can they own over 100% of the shares well if you take into account the 25% short interest there ya go
This was over 20$+ not that long ago virtually NO FLOAT
Also Confintantal agreement filing as well
Book value is at 25$ per share
https://finance.yahoo.com/quote/FTFT/key-statistics?p=FTFT
Given the fact that there is virtually NO Float to trade on this one thing all ready trading next to no volume because well there is virtually no shares left for the public to trade and the chart this was 20$+ not that long ago any news and this thing can fly and burn the shorts all the way up
Company is also spose to close on a 100 Million Dollar deal by the end of the year so that news could come at anytime... Bottom of the chart dirt cheap down here 97 Million in retained earnings